Clinical Trials

Cardurion Pharmaceuticals announced it has entered an exclusive licensing agreement with Astellas to develop and commercialize CRD-733, a PDE-9 inhibitor with the potential to improve…
Read More...

“This milestone showcases the productivity of our collaboration with LEO Pharma, marking the final step before ARGX-112 may enter clinical development. It triggers the third of three…
Read More...

Pfizer has joined the TriNetX global health research network. As a member, Pfizer will have access to clinical data from TriNetX's network of healthcare organizations to support…
Read More...

Protalex, Inc. announced that the Company has enrolled the first of three patients in cohort four of its U.S./U.K. Phase 1/2 trial evaluating PRTX-100 for the treatment of adults with…
Read More...

PhaseBio Pharmaceuticals announced that it has completed dosing in the first cohort of subjects in its Phase 1 clinical trial of PB2452 (formerly MEDI2452), a reversal agent for the…
Read More...

MyoKardia, Inc. announced that the first patient has been dosed in the company’s Phase 2 MAVERICK-HCM clinical trial. MAVERICK-HCM is the first clinical trial of mavacamten in…
Read More...

MRI analysis of patients who received intradiscal injections of human dermal fibroblasts (HDFs) shows significant improvement in disc height after six months. This is the latest…
Read More...

PharmaCyte Biotech, Inc. announced that vials of cells from PharmaCyte’s Master Cell Bank (MCB) have been shipped by Eurofins Lancaster Laboratories (Eurofins) to Austrianova’s…
Read More...

Synlogic announced that the first patient was dosed in its Phase 1b/2a clinical trial of SYNB1020. SYNB1020 is a Synthetic Biotic medicine being developed for the treatment of…
Read More...

Clinipace Worldwide has announced the appointment of Ian Fraser as senior vice president of operations for the European Union and Middle East (EUME). In his new role, Fraser will lead…
Read More...

Arrowhead Pharmaceuticals announced that it has dosed the first subjects in a Phase 1/2 clinical study of ARO-HBV, which is being developed as a potentially curative therapy for…
Read More...

Pfizer Inc. announced results from a Phase 4 study evaluating the efficacy and safety of CHANTIX/CHAMPIX (varenicline) for smoking cessation in nicotine dependent adolescents 12-19…
Read More...

Flex Pharma announced positive topline data for FLX-787 from its exploratory Phase 2 trial in MS patients with frequent muscle cramps/spasms and spasticity. “MS patients frequently…
Read More...

vTv Therapeutics Inc. announced the completion of Phase 1b of Simplici-T1, an adaptive Phase 1b/2 study assessing the pharmacokinetics, pharmacodynamics, safety and tolerability of…
Read More...

Intezyne announced that it has partnered with Exosome Diagnostics, a privately held company focused on developing and commercializing revolutionary biofluid-based diagnostics, to design…
Read More...

Elligo Health Research, which improves clinical trial access by engaging the 97 percent of physicians currently not offering clinical research to their patients, announced today $16…
Read More...

Intezyne, a clinical-stage biopharmaceutical company developing novel anti-cancer therapies, announced that it has partnered with Exosome Diagnostics, a privately held company focused…
Read More...

PAREXEL International Corporation announced an alliance with CHA Medical Group (CHA) to enhance early phase clinical development in Korea. The collaboration is designed to provide…
Read More...

Merriimack Pharmaceuticals which is a clinical-stage oncology company focused on biomarker-defined cancers asserted that it is augmenting enrollment in the ongoing randomized Phase 2…
Read More...

BioVentrix announced successful treatment of the first patient at the Cardiovascular Institute of the South in the ALIVE pivotal clinical trial. The trial is designed to demonstrate the…
Read More...